Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01690624
Other study ID # 1315.1
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date September 13, 2012
Est. completion date May 21, 2018

Study information

Verified date May 2018
Source Boehringer Ingelheim
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with acute myeloid leukemia who experience a relapse after at least one prior regimen may be enrolled in this trial. In addition, acute myeloid leukemia patients who are in complete remission with high risk to relapse may be eligible for this trial. The trial will examine whether monotherapy with BI 836858 is safe and tolerable at escalating dose levels.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date May 21, 2018
Est. primary completion date May 21, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria:

1. Diagnosis of relapsed or refractory AML with at least one prior treatment for acute myeloid leukemia and patients with diagnosis of acute myeloid leukemia in complete remission with high risk to relapse.

2. Expression of CD33 on more than 30% of bone marrow blasts at screening for patients with refractory or relapsed acute myeloid leukemia is required. CD33 positive expression of bone marrow blasts at the time of initial acute myeloid leukemia diagnosis is sufficient for those patients in complete remission with high risk to relapse.

3. Eastern Cooperative Oncology Group Performance Status 0, 1 or 2

4. Age 18 years or older

5. Written informed consent which is consistent with International Conference on Harmonization, Good Clinical Practice (ICH-GCP) guidelines and local legislation.

Exclusion criteria:

1. Patients with acute promyelocytic leukemia according to WHO definition.

2. Patients with refractory or relapsed acute myeloid leukemia > 5.000 blasts in the peripheral blood.

3. Anti-leukemia therapy within two weeks before first treatment with BI 836858, 4 weeks for biologics. Parallel treatment with Hydroxyurea ia allowed with refractory or relapsed acute myeloid leukemia patients.

4. Allogeneic stem cell transplantation within the last 28 days before first treatment with graft versus host disease requiring more than 20 mg of steroids per day. Steroid dosage must be stable within two weeks prior to start of treatment.

5. Patients who are candidates for allogeneic stem cell transplantation (for patients with refractory or relapsed acute myeloid leukemia).

6. Second malignancy currently requiring active therapy.

7. Symptomatic central nervous system involvement

8. Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (ULN), or AST or ALT greater than 5 times the ULN for those with Gilbert syndrome.

9. Prothrombin time (PT) >1.5 x ULN for subjects not on therapeutic vitamin K antagonists (phenprocoumon, warfarin)

10. Bilirubin greater than 1.5 mg/dl (>26 µmol/L) unless elevation is thought to be due to hepatic infiltration by AML, Gilbert syndrome, or hemolysis.

11. Serum creatinine greater than 2.0 mg/dl

12. Known human immunodeficiency virus (HIV) infection or active hepatitis B virus or hepatitis C virus infection.

13. Concomitant intercurrent illness, or any condition which in the opinion of the Investigator, would compromise safe participation in the study, e.g. active severe infection, unstable angina pectoris, new onset of exacerbation of a cardiac arrhythmia

14. Psychiatric illness or social situation that would limit compliance with trial requirements

15. Concomitant therapy, which is considered relevant for the evaluation of the efficacy or safety of the trial drug

16. Female patients of childbearing potential who are sexually active and unwilling to use a medically acceptable method of contraception during the trial and for 6 months after the last administration of BI 836858

17. Male patients with partners of childbearing potential who are unwilling to use condoms in combination with a second effective method of contraception during the trial and for 6 months after the last administration of BI 836858

18. Pregnant or nursing female patients

19. Treatment with another investigational agent under the following conditions:

1. Within two weeks (4 weeks for biologics or 5 half-lives, whichever is longer) of first administration of BI 836858; or

2. Patient has persistent toxicities from prior anti-leukemic therapies which are determined to be relevant by the Investigator.

3. Concomitant treatment with another investigational agent while participating in this trial.

20. Prior treatment with a CD33 antibody

21. Patient unable or unwilling to comply with the protocol.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
BI 836858
Monotherapy with BI 836858 administered as intravenous infusion

Locations

Country Name City State
United States Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Baltimore Maryland
United States Northwestern University Chicago Illinois
United States The Ohio State University Wexner Medical Center Columbus Ohio
United States Memorial Sloan-Kettering Cancer Center New York New York
United States Washington University School of Medicine Saint Louis Missouri

Sponsors (1)

Lead Sponsor Collaborator
Boehringer Ingelheim

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determination of the maximum tolerated dose of BI 836858 up to 4 weeks
Primary Number of patients with dose limiting toxicity during maximum tolerated dose evaluation for patients with refractory or relapsed acute myeloid leukemia up to 4 weeks
Primary Number of patients with dose limiting toxicity during maximum tolerated dose evaluation for acute myeloid leukemia patients in complete remission with high risk to relapse up to 4 weeks
Secondary Maximum measured plasma concentration (Cmax) up to 168 hours
Secondary Time from dosing to the maximum plasma concentration (tmax) up to 168 hours
Secondary Area under the plasma concentration-time curve over the time interval of one week (AUC0-168) up to 168 hours
Secondary Area under the plasma concentration-time curve over the time interval of one treatment cycle (AUC0-tz) up to 336 hours
Secondary Area under the plasma concentration-time curve over the time interval from zero extrapolated to infinity (AUC0-infinity) up to 168 hours
Secondary Terminal half-life (t1/2) up to 168 hours
Secondary Mean residence time after intravenous infusion (MRT) up to 168 hours
Secondary Total plasma clearance (CL) up to 168 hours
Secondary Apparent volume of distribution during the terminal phase (Vz) up to 168 hours
Secondary Volume of distribution after intravenous infusion at steady state (Vss) up to 168 hours
Secondary Area under the plasma concentration-time curve over the time interval from zero to the time of the last quantifiable data point (AUC0-tz) up to 168 hours
Secondary Best overall response rate according to International Working Group (IWG) criteria (for refractory or relapsed acute myeloid leukemia patients only) up to 22 months
Secondary Progression free survival for patients with refractory or relapsed acute myeloid leukemia up to 22 months
Secondary Time to treatment failure for patients with refractory or relapsed acute myeloid leukemia up to 22 months
Secondary Time to treatment failure for acute myeloid leukemia patients in complete remission with high risk to relapse up to 22 months
Secondary Progression free survival for acute myeloid leukemia patients in complete remission with high risk to relapse up to 22 months
See also
  Status Clinical Trial Phase
Recruiting NCT05319587 - Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML) Phase 1/Phase 2
Active, not recruiting NCT04090736 - Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy Phase 3
Completed NCT01617226 - Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS Phase 2
Terminated NCT00916045 - Pilot Study of Unrelated Cord Blood Transplantation Phase 2
Terminated NCT00957580 - Trial of Pimasertib in Hematological Malignancies Phase 2
Completed NCT00640796 - Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors Phase 1
Completed NCT00458250 - Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H Phase 1
Active, not recruiting NCT05424380 - A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS Phase 1
Recruiting NCT05471700 - Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients Phase 1/Phase 2
Not yet recruiting NCT05016063 - Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Early Phase 1
Not yet recruiting NCT04450784 - ObServatory Children Acute RElated Therapy Leukemia
Recruiting NCT04265963 - CD123-Targeted CAR-T Cell Therapy for Relapsed/Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Terminated NCT04968860 - Oral Health Condition and Quality of Life in Children With Leukemia
Recruiting NCT03793517 - Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT Phase 2/Phase 3
Terminated NCT02841540 - A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes Phase 1
Recruiting NCT05453903 - A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies Phase 1
Completed NCT03720366 - A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients Phase 1
Withdrawn NCT04230564 - Acute Myeloid Leukemia Real World Treatment Patterns
Terminated NCT03761069 - Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias Phase 1
Completed NCT01835587 - Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS). Phase 1/Phase 2